<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A subset of women with <z:e sem="disease" ids="C0153567" disease_type="Neoplastic Process" abbrv="">uterine cancer</z:e> exhibiting defective mismatch repair (MMR) proteins and microsatellite instability (MSI) may have <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>, which also confers a risk for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in the patient and in her family </plain></SENT>
<SENT sid="1" pm="."><plain>Screening algorithms based on clinical and pathologic criteria are effective in determining which patients with <z:e sem="disease" ids="C0153567" disease_type="Neoplastic Process" abbrv="">uterine cancer</z:e> are most likely to benefit from definitive genetic testing for <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">Ovarian cancer</z:e>, particularly endometrioid <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, is also associated with <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>, although the risk is much smaller than for <z:e sem="disease" ids="C0153567" disease_type="Neoplastic Process" abbrv="">uterine cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This study evaluated whether the morphologic criteria [<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating lymphocytes (TILs), peritumoral lymphocytes (PTLs), dedifferentiated <z:mp ids='MP_0000002'>morphology</z:mp>)] currently used to screen <z:e sem="disease" ids="C0153567" disease_type="Neoplastic Process" abbrv="">uterine cancer</z:e> for further <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> testing can be applied to <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Among 71 patients with pure ovarian endometrioid <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> treated at a single institution, 13% had a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> with TILs, 3% had PTLs, and none had dedifferentiated <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, 10% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had <z:mp ids='MP_0009797'>abnormal MMR</z:mp> protein status, defined as complete immunohistochemical loss of expression of MLH1, MSH2, MSH6, and/or PMS2 </plain></SENT>
<SENT sid="6" pm="."><plain>Each of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with <z:mp ids='MP_0009797'>abnormal MMR</z:mp> status demonstrated MSI using a polymerase chain reaction-based assay evaluating 5 mononucleotide repeat markers </plain></SENT>
<SENT sid="7" pm="."><plain>No relationship was found between patient age, TILs, PTLs, or a spectrum of other morphologic variables and MMR protein status/MSI </plain></SENT>
<SENT sid="8" pm="."><plain>Only 1/7 tumors with <z:mp ids='MP_0009797'>abnormal MMR</z:mp>/MSI had TILs/PTLs </plain></SENT>
<SENT sid="9" pm="."><plain>Among 14 patients who died, 12 (86%) had <z:mpath ids='MPATH_458'>normal</z:mpath> MMR status </plain></SENT>
<SENT sid="10" pm="."><plain>Among 7 patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with <z:mp ids='MP_0009797'>abnormal MMR</z:mp>/MSI, 5 (71%) were alive without disease </plain></SENT>
<SENT sid="11" pm="."><plain>Concurrent <z:mp ids='MP_0009222'>uterine tumor</z:mp> was present in 5/7 patients whose <z:mp ids='MP_0008000'>ovarian tumor</z:mp> had <z:mp ids='MP_0009797'>abnormal MMR</z:mp>/MSI </plain></SENT>
<SENT sid="12" pm="."><plain>This study suggests that the morphologic criteria used to screen patients with <z:e sem="disease" ids="C0153567" disease_type="Neoplastic Process" abbrv="">uterine cancer</z:e> for further <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> testing are not applicable in patients with <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Although <z:mp ids='MP_0009797'>abnormal MMR</z:mp>/MSI did not carry prognostic value in this study, it did predict the involvement of the uterus by the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Thus, in patients with ovarian endometrioid <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> who undergo uterus-sparing surgery, <z:mp ids='MP_0009797'>abnormal MMR</z:mp>/MSI should prompt further diagnostic evaluation of the endometrium for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>